Scott Galloway says GLP-1 drugs are a ‘silver bullet’ for America’s woes, if we’re not ‘stupid enough’ to get in the way
On June 12, SpaceX (NASDAQ: SPCX) had the biggest IPO on record, making $75 billion (1) — but…
Warning issued over counterfeit weight-loss drugs labelled as retatrutide
Senior doctors from a hospital in Melbourne’s north are warning people against taking drugs being labelled as experimental…
The Latest Ozempic Side Effect? It May Make You Less Violent
Topline GLP-1 medications like Ozempic and Wegovy may reduce the risk of violent criminal behavior among current users,…
Novo Nordisk comeback stirs as Wegovy pill wins UK approval
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk’s Wegovy (semaglutide) pill, marking another…
New Weight Loss Drug Could Beat Ozempic’s Results—When It’s Coming
A new experimental weight loss drug from Eli Lilly could produce greater weight loss results than popular medications…
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
The global geopolitical landscape has plunged into a deep state of uncertainty once again following a direct exchange…
Can Wegovy Pill’s Rapid Uptake Give Novo Nordisk an Edge Over LLY?
Novo Nordisk NVO remains one of the dominant players in the rapidly expanding obesity treatment market. The company markets…
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
The pharmaceutical industry is highly technical and incredibly competitive. That is on clear display right now in the…
3 Reasons Eli Lilly Remains a Buy
Eli Lilly (NYSE: LLY) became the first $1 trillion pharmaceutical company late last year, built on the strength…
US pharma giant Eli Lilly is very unhappy with Germany; CEO calls its planned healthcare reform: Terrible signal to …
US pharmaceutical giant Eli Lilly has announced that it is halving its massive €2.3 billion ($2.67 billion) investment…
Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry
Quick Read NVIDIA and Eli Lilly’s $1 billion AI drug discovery partnership makes both stocks the primary public…
Forget Zepbound: Eli Lilly’s Next Billion-Dollar Weight-Loss Drug May Be Even Better
Eli Lilly (NYSE: LLY) has been posting incredible sales and earnings growth in recent quarters, thanks in no…